Prokofjeva M M, Kochetkov S N, Prassolov V S
Engelhardt Institute of Molecular Biology, Vavilova Str., 32, Moscow, 119991, Russia.
Acta Naturae. 2016 Oct-Dec;8(4):23-32.
The human immunodeficiency virus type 1 (HIV-1) is the causative agent of one of the most dangerous human diseases - the acquired immune deficiency syndrome (AIDS). Over the past 30 years since the discovery of HIV-1, a number of antiviral drugs have been developed to suppress various stages of the HIV-1 life cycle. This approach has enables the suppression of virus replication in the body, which significantly prolongs the life of HIV patients. The main downside of the method is the development of viral resistance to many anti-HIV drugs, which requires the creation of new drugs effective against drug-resistant viral forms. Currently, several fundamentally new approaches to HIV-1 treatment are under development, including the use of neutralizing antibodies, genome editing, and blocking an integrated latent provirus. This review describes a traditional approach involving HIV-1 inhibitors as well as the prospects of other treatment options.
人类免疫缺陷病毒1型（HIV-1）是最危险的人类疾病之一——获得性免疫缺陷综合征（艾滋病）的病原体。自发现HIV-1以来的过去30年里，已经开发出多种抗病毒药物来抑制HIV-1生命周期的各个阶段。这种方法能够抑制体内病毒复制，显著延长了HIV患者的寿命。该方法的主要缺点是病毒对许多抗HIV药物产生耐药性，这就需要研发对耐药病毒形式有效的新药。目前，几种全新的HIV-1治疗方法正在研发中，包括使用中和抗体、基因组编辑以及阻断整合的潜伏前病毒。本综述描述了涉及HIV-1抑制剂的传统方法以及其他治疗选择的前景。
